Sapient Capital LLC Sells 10,520 Shares of Gilead Sciences, Inc. $GILD

Sapient Capital LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 162,826 shares of the biopharmaceutical company’s stock after selling 10,520 shares during the period. Sapient Capital LLC’s holdings in Gilead Sciences were worth $22,684,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences in the 4th quarter valued at $517,808,000. Massachusetts Financial Services Co. MA lifted its holdings in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after purchasing an additional 4,113,999 shares during the last quarter. Bank of America Corp DE boosted its position in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. boosted its position in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $130.21 on Monday. The company has a market capitalization of $161.66 billion, a price-to-earnings ratio of 17.74 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm’s 50-day moving average price is $129.61 and its two-hundred day moving average price is $135.96.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period last year, the firm earned $1.81 EPS. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gilead Sciences in a report on Wednesday. Citigroup upped their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Royal Bank Of Canada cut their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $157.93.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,000 shares of company stock valued at $8,687,140 over the last three months. 0.30% of the stock is owned by insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Gilead’s Trodelvy with Keytruda for certain patients with advanced triple-negative breast cancer. The potential label expansion could broaden Trodelvy’s commercial opportunity and strengthen Gilead’s oncology pipeline. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: Several analyses remain favorable on GILD. One investment article argues that investors should “buy the distortion” ahead of second-quarter results, while another says the stock still appears inexpensive after delivering roughly 130% total return over five years. Gilead: Buy the Distortion Before Q2 Clears It Up Gilead Stock Stays Cheap on Its Five-Year Run
• Neutral Sentiment: Investor attention is focused on Gilead’s second-quarter 2026 results. Preview articles highlight Wall Street expectations for revenue, earnings and operating metrics, but they do not provide a confirmed earnings surprise. Wall Street Projections for Gilead’s Q2 Metrics
• Positive Sentiment: Analyst coverage remains broadly supportive, with reports noting Gilead’s market outperformance and bullish views on its prospects. However, heightened investor attention alone is not a fundamental catalyst. Do Wall Street Analysts Like Gilead Sciences Stock?
• Negative Sentiment: Erste Group Bank reduced its fiscal 2027 earnings-per-share estimate for Gilead, raising concerns about the company’s future earnings growth. Erste Group Bank Cuts Gilead FY2027 EPS Estimate
• Negative Sentiment: Barclays lowered its Gilead price target to $145. Although the revised target remains above the stock’s referenced trading level, the reduction signals more limited near-term upside and is likely weighing on sentiment. Barclays Lowers Gilead Price Target

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.